← Browse by Condition
Medical Condition

hypertensive disorders of pregnancy

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 4

ClinicalMetric tracks all active clinical trials for hypertensive disorders of pregnancy sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — hypertensive disorders of pregnancy Clinical Trials

How many clinical trials are currently recruiting for hypertensive disorders of pregnancy?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for hypertensive disorders of pregnancy, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for hypertensive disorders of pregnancy?
hypertensive disorders of pregnancy research spans Phase 4 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a hypertensive disorders of pregnancy clinical trial?
Eligibility criteria for hypertensive disorders of pregnancy trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 4
1
Top Sponsors
Ohio State University 1 trial
Ammar Jassim Abed 1 trial
Forgive Avorgbedor 1 trial

Recruiting Clinical Trials

NCT06468202 Phase 4
Recruiting
Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL
Enrollment
10,742 pts
Location
United States
Sponsor
Ohio State University
View Trial →
NCT07349277
Recruiting
Evaluation of sFlt-1/PlGF Ratio ,OPG and sEng as Predictive Biomarkers in the Diagnosis and Treatment Evaluation of Preeclampsia
Enrollment
120 pts
Location
Iraq
Sponsor
Ammar Jassim Abed
View Trial →
NCT07420465
Recruiting
Cardiometabolic Risk in Pregnancy and Postpartum
Enrollment
200 pts
Location
Ghana
Sponsor
Forgive Avorgbedor
View Trial →

Related Conditions

preeclampsia (2) gestational hypertension (2) postpartum hypertension (1) cardiovascular disease risk (1) high blood pressure (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology